Founded in 2015, Fulmz Technology focuses on using AI technology to improve the efficiency of early development of new drugs through in-depth cooperation with CRO and original pharmaceutical companies.

Fulmz is specialized in the field of central nervous system (CNS), autoimmunity and refractory tumors and aimed to develop differentiated Best-In-Class or First-In-Class pipelines. Drug Studio AI, its self-developed drug development platform, is utilized to solve problems related to drug tissue targeting and high selectivity.